Although neither the DSM nor the International Classification of Diseases (ICD) formally recognizes addiction to highly palatable foods as a clinical diagnosis (LaFata et al., 2025), there is nevertheless a notable parallel between substance use disorders and certain patterns of eating behavior
The mechanism of GLP-1 agonists involves slowing gastric emptying, which prolongs the feeling of fullness after eating and, in turn, tends to reduce the frequency of eating
Hydropersulfides inhibit lipid peroxidation and protect cells from ferroptosis
General GI symptoms were the most frequently mentioned side effects
Have a BMI of 27 or higher Semaglutide is not a miracle weight loss pill
Slide from Katherine Tuttles presentation, during FLOW session, 61st European Renal Association Congress Conclusion The FLOW trial showed that semaglutide significantly decreased the risk of progression of kidney disease in T2DM, without significant increases in serious adverse events